Division of Ear, Nose and Throat Diseases, CLINTEC, Karolinska Institutet, Karolinska University Hospital, Huddinge, Sweden.
Respir Res. 2010 Jan 29;11(1):13. doi: 10.1186/1465-9921-11-13.
Nicotine plays an important role in cigarette-smoke-associated airway disease. The present study was designed to examine if nicotine could induce airway hyperresponsiveness through kinin receptors, and if so, explore the underlying mechanisms involved.
Murine tracheal segments were cultured for 1, 2 or 4 days in serum-free DMEM medium in presence of nicotine (1 and 10 microM) or vehicle (DMSO). Contractile responses induced by kinin B1 receptor agonist, des-Arg9-bradykinin, and B2 receptor agonist, bradykinin, were monitored with myographs. The B1 and B2 receptor mRNA expressions were semi-quantified using real-time PCR and their corresponding protein expressions assessed with confocal-microscopy-based immunohistochemistry. Various pharmacological inhibitors were used for studying intracellular signaling pathways.
Four days of organ culture with nicotine concentration-dependently increased kinin B1 and B2 receptor-mediated airway contractions, without altering the kinin receptor-mediated relaxations. No such increase was seen at day 1 or day 2. The airway contractile responses to 5-HT, acetylcholine and endothelin receptor agonists remained unaffected by nicotine. Two different neuronal nicotinic receptor antagonists MG624 and hexamethonium blocked the nicotine-induced effects. The enhanced contractile responses were accompanied by increased mRNA and protein expression for both kinin receptors, suggesting the involvement of transcriptional mechanisms. Confocal-microscopy-based immunohistochemistry showed that 4 days of nicotine treatment induced activation (phosphorylation) of c-Jun N-terminal kinase (JNK), but not extracellular signal-regulated kinase 1 and 2 (ERK1/2) and p38. Inhibition of JNK with its specific inhibitor SP600125 abolished the nicotine-induced effects on kinin receptor-mediated contractions and reverted the enhanced receptor mRNA expression. Administration of phosphodiesterase inhibitors (YM976 and theophylline), glucocorticoid (dexamethasone) or adenylcyclase activator (forskolin) suppressed the nicotine-enhanced airway contractile response to des-Arg9-bradykinin and bradykinin.
Nicotine induces airway hyperresponsiveness via transcriptional up-regulation of airway kinin B1 and B2 receptors, an effect mediated via neuronal nicotinic receptors. The underlying molecular mechanisms involve activation of JNK- and PDE4-mediated intracellular inflammatory signal pathways. Our results might be relevant to active and passive smokers suffering from airway hyperresponsiveness, and suggest new therapeutic targets for the treatment of smoke-associated airway disease.
尼古丁在与吸烟有关的气道疾病中起着重要作用。本研究旨在探讨尼古丁是否可以通过激肽受体诱导气道高反应性,如果是这样,那么探索涉及的潜在机制。
在无血清 DMEM 培养基中,将鼠气管段培养 1、2 或 4 天,存在尼古丁(1 和 10 μM)或载体(DMSO)。使用肌动描记器监测激肽 B1 受体激动剂,去精氨酸 9-缓激肽和 B2 受体激动剂,缓激肽引起的收缩反应。使用实时 PCR 对 B1 和 B2 受体 mRNA 表达进行半定量,并使用基于共聚焦显微镜的免疫组织化学评估其相应的蛋白表达。使用各种药理学抑制剂研究细胞内信号通路。
4 天的器官培养物中,尼古丁浓度依赖性地增加了激肽 B1 和 B2 受体介导的气道收缩,而不改变激肽受体介导的松弛。在第 1 天或第 2 天没有看到这种增加。5-HT、乙酰胆碱和内皮素受体激动剂引起的气道收缩反应不受尼古丁影响。两种不同的神经元烟碱受体拮抗剂 MG624 和六烃季铵阻断了尼古丁的作用。增强的收缩反应伴随着两种激肽受体的 mRNA 和蛋白表达增加,表明涉及转录机制。基于共聚焦显微镜的免疫组织化学显示,4 天的尼古丁处理诱导了 c-Jun N-末端激酶(JNK)的激活(磷酸化),但不诱导细胞外信号调节激酶 1 和 2(ERK1/2)和 p38。用其特异性抑制剂 SP600125 抑制 JNK 消除了尼古丁对激肽受体介导的收缩的作用,并使增强的受体 mRNA 表达恢复正常。给予磷酸二酯酶抑制剂(YM976 和茶碱)、糖皮质激素(地塞米松)或腺苷酸环化酶激活剂(forskolin)抑制尼古丁增强的去精氨酸 9-缓激肽和缓激肽对气道收缩的反应。
尼古丁通过转录上调气道激肽 B1 和 B2 受体诱导气道高反应性,这种作用通过神经元烟碱受体介导。潜在的分子机制涉及 JNK 和 PDE4 介导的细胞内炎症信号通路的激活。我们的结果可能与患有气道高反应性的主动和被动吸烟者有关,并为治疗与吸烟有关的气道疾病提供了新的治疗靶点。